-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Sodium molybdate is an acid phosphatase inhibitor. The osteoclastic acid phosphatase isoenzyme, secreted by osteoclasts, is a member of a widely-distributed class of iron-containing proteins with acid phosphatase activity. Elevated plasma isoenzyme levels are associated with increased bone turnover in metabolic disease. By inhibiting this class of acid phosphatases, sodium molybdate is capable of abolishing bone resorption. In addition, sodium molybdate has been shown to stabilize the nonactivated glucocorticoid-receptor complex.
1. Zaidi M, Moonga B, Moss DW, et al. Inhibition of osteoclastic acid phosphatase abolishes bone resorption. Biochemical and Biophysical Research Communications, 1989, 159(1): 68-71.
2. Denis M, Wikström AC, Gustafsson JA. The molybdate-stabilized nonactivated glucocorticoid receptor contains a dimer of Mr 90,000 non-hormone-binding protein. Journal of Biological Chemistry, 1987, 262(24): 11803-11806.
-
- Properties
-
Overview